The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 66 , ISSUE 1 ( January-March, 2024 ) > List of Articles

Original Article

A Cross-sectional Study on Assessment of Estimated Glomerular Filtration Rate in Patients with Stable Chronic Obstructive Pulmonary Disease

Soumitra Mondal, Sabyasachi Choudhury, Kaushik Saha, Subir K Dey, Sibes K Das, Gopal Sasmal

Keywords : Chronic obstructive pulmonary disease, Estimated glomerular filtration rate, Global Initiative for chronic obstructive lung disease stage, Renal involvement

Citation Information : Mondal S, Choudhury S, Saha K, Dey SK, Das SK, Sasmal G. A Cross-sectional Study on Assessment of Estimated Glomerular Filtration Rate in Patients with Stable Chronic Obstructive Pulmonary Disease. Indian J Chest Dis Allied Sci 2024; 66 (1):7-10.

DOI: 10.5005/jp-journals-11007-0104

License: CC BY-NC 4.0

Published Online: 03-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Background: Chronic obstructive pulmonary disease (COPD) is a systemic disease with several extrapulmonary comorbidities. However, studies to find out the relationship between COPD and renal impairment are scarce. This study aimed to assess the relationship of estimated glomerular filtration rate (eGFR) with chronic obstructive pulmonary disease assessment test (CAT) score, modified medical research council (mMRC) scale, 6-minute walking test (6MWT), and postbronchodilator forced expiratory volume (FEV1) in COPD and to compare the reduction of eGFR in different GOLD stages. Materials and methods: A total of 240 stable COPD patients attending the outpatient department (OPD) were randomly selected between November 2019 and October 2020. Participants had spirometry, Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging, CAT score, mMRC grading, and 6MWT. Serum creatinine was obtained and eGFR was calculated. The interpretation was made by comparing the results of the eGFR and GOLD stages with different parameters. Results: In patients with normal eGFR, the mean mMRC score was 2.00 ± 0.86, 6MWD was 324.98 ± 47.08 m, and CAT score was 14.23± 6.09. With reduced eGFR, the mean mMRC score was 2.32 ± 1.17, 6MWD was 278.30 ± 75.98 m, and CAT scoring was 19.38 ± 9.05. These were statistically significant (p = 0.0145, p < 0.0001, and p < 0.0001, respectively). A negative correlation was found between eGFR vs GOLD stages; the Pearson correlation coefficient (r) was −0.014. Conclusion: Reduction of eGFR was seen in stable COPD patients with higher GOLD stages. Patients with reduced eGFR had higher mMRC grade, increased CAT score, and reduced 6MWD. So, routine estimation of eGFR in patients of stable COPD is advocated to assess renal involvement.

PDF Share
  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease – 2020 report. 2023–2024. Available at: Accessed on: 22 May 2023.
  2. Barnes PJ, Celli BR. Systemic manifestation and comorbidities of COPD. Eur Respir J 2009;33(5):1165–1185. DOI: 10.1183/09031936.00128008.
  3. The Kidney Disease: Improving Global Outcomes (KDIGO). 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). 2024. Available at: Accessed on: 2 April 2023.
  4. Nangaku M. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17(1):17–25. DOI: 10.1681/ASN.2005070757.
  5. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics. Kidney Int 2008;74(7):867–872. DOI: 10.1038/ki.2008.350.
  6. John M, Hussain S, Prayle A, et al. Target renal damage: The microvascular associations of increased aortic stiffness in patients with COPD. Respir Res 2013;14(1):31. DOI: 10.1186/1465-9921- 14-31.
  7. Sofia M, Maniscalco M, Celentano L, et al. Abnormalities of renal endothelin during acute exacerbation in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2001;14(4):321–327. DOI: 10.1006/pupt.2001.0303.
  8. Gembillo G, Calimeri S, Tranchida V, et al. Lung dysfunction and chronic kidney disease: A complex network of multiple interactions. J Pers Med 2023;13(2):286. DOI: 10.3390/jpm13020286.
  9. Elmahallawy II, Qora MA. Prevalence of chronic renal failure in COPD patients. Egyptian J Chest Diseases Tuberculosis 2013;62(2):221–227. DOI: 10.1016/j.ejcdt.2013.02.005.
  10. Mapel D, Marton JP. Prevalence of renal and hepatobiliary disease, laboratory abnormalities, and potentially toxic medication exposures among persons with COPD. Int J Chron Obstruct Pulmon Dis 2013:8:127–134. DOI: 10.2147/COPD.S40123.
  11. Chen CY, Liao KM. Chronic obstructive pulmonary disease is associated with risk of chronic kidney disease: A nationwide case–cohort study. Sci Rep 2016;6:25855. DOI: 10.1038/srep25855.
  12. AbdelHalim HA, AboElNaga HH. Is renal impairment an anticipated COPD comorbidity? Respir Care 2016;61(9):1201–1206. DOI: 10.4187/respcare.04516.
  13. Pelaia C, Pastori D, Armentaro G, et al. Predictors of renal function worsening in patients with chronic obstructive pulmonary disease (COPD): A multicenter observational study. Nutrients 2021;13(8):2811. DOI: 10.3390/nu13082811.
  14. Kim SK, Bae JC, Baek JH, et al. Is decreased lung function associated with chronic kidney disease? A retrospective cohort study in Korea. BMJ Open 2018;8(4):e018928. DOI: 10.1136/bmjopen-2017- 018928.
  15. Kim SH, Kim HS, Min HK, et al. Obstructive spirometry pattern and the risk of chronic kidney disease: Analysis from the community-based prospective Ansan–Ansung cohort in Korea. BMJ Open 2021;11:e043432. DOI: 10.1136/bmjopen-2020-043432.
  16. Shihong Li, Zhang L, Zhang Y, et al. Renal impairment in patients with chronic obstructive pulmonary disease: Retrospective observational study. Int J Clin Exp Med 2018;11(2):1285–1290. Available from: in-patients-with-chronic-pulmonary-Li-Zhang/e5088327b9632f2b9 e16a98f8f828362af4ed2b6. Corpus ID: 165154322.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.